1. Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.
- Author
-
Funazo TY, Nomizo T, Ozasa H, Tsuji T, Yasuda Y, Yoshida H, Sakamori Y, Nagai H, Hirai T, and Kim YH
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological adverse effects, B7-H1 Antigen genetics, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Drug-Related Side Effects and Adverse Reactions blood, Drug-Related Side Effects and Adverse Reactions etiology, Female, Follow-Up Studies, Humans, Lung Neoplasms genetics, Lung Neoplasms pathology, Male, Middle Aged, Prognosis, Programmed Cell Death 1 Receptor genetics, Retrospective Studies, Survival Rate, Thyroid Function Tests, Biomarkers, Tumor analysis, Carcinoma, Non-Small-Cell Lung drug therapy, Drug-Related Side Effects and Adverse Reactions diagnosis, Lung Neoplasms drug therapy, Nivolumab adverse effects, Polymorphism, Single Nucleotide, Thyroxine blood
- Abstract
Nivolumab improves the prognosis of non-small cell lung cancer (NSCLC) but can cause immune-related adverse events (irAEs). Reports have indicated longer progression-free survivals (PFSs) in patients with irAEs than in those without irAEs. We reported associations between programmed death ligand-1 (PD-L1) single nucleotide polymorphisms (SNPs) and PFS after nivolumab treatment. We hypothesized that adverse events might be associated with the SNPs of PD-L1. We analyzed data from 111 patients with NSCLC treated with nivolumab. The response rate was 14%, and the median PFS was 68 days. We found patients with the adverse event of low free tetraiodothyronine (fT4) had significantly longer PFSs than those without low fT4 (not reached vs 67 days; hazard ratio [HR], 0.297; P = 0.010). Moreover, median overall survival was longer in patients with low fT4 than those without low fT4 (not reached vs 556 days, HR, 0.139; P = 0.020). Patients with the T allele of rs1411262 (P = 0.0073) and with the A allele of rs822339 (P = 0.0204) developed low fT4. Patients with the T/T genotype had longer PFSs than with those with the C/T and C/C genotypes of rs1411262 (165 vs. 67 days, HR, 1.65; P = 0.040), and those with the A/A genotype had longer PFSs than those with the A/G and G/G genotypes of rs822339 (182 vs. 67 days, HR, 1.76; P = 0.025). In the patients with advanced NSCLC, low fT4 after nivolumab treatment was associated with significantly longer PFSs. The SNPs of PD-L1 may be associated with the adverse events of nivolumab.
- Published
- 2019
- Full Text
- View/download PDF